Preview Mode Links will not work in preview mode

Mar 14, 2019

Pancreatic Cancer Update – Part 1: Our interview with Dr. Ko highlights the following topics as well as cases from his practice:

  • Case: A 45-year-old woman with borderline resectable adenocarcinoma of the pancreas attains an excellent response to neoadjuvant FOLFIRINOX: 0m0s
  • Role of genetic counseling and molecular profiling for patients with pancreatic cancer: 1m42s
  • Effects of mutational load and PD-L1 expression on response to immunotherapy: 4m34s
  • Pathophysiology of pancreatic cancer: 5m43s
  • Radiographic criteria for defining resectable versus borderline resectable disease and implications for therapy: 8m3s
  • Response and tolerability with neoadjuvant FOLFIRINOX: 12m14s
  • Ongoing Phase II SWOG-S1505 trial of perioperative modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine/nab paclitaxel for resectable adenocarcinoma of the pancreas: 17m22s
  • Efficacy of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: 20m6s
  • Case: A 78-year-old man with resected pancreatic cancer treated with adjuvant single-agent gemcitabine: 24m56s
  • Risk of recurrence for patients with resectable pancreatic cancer: 28m31s
  • Results from the Phase III PRODIGE 24/CCTG PA.6 trial evaluating adjuvant mFOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma: 32m25s
  • Risks and benefits with nab paclitaxel/gemcitabine and FOLFIRINOX as adjuvant therapy: 33m49s
  • Case: A 70-year-old man with metastatic adenocarcinoma of the pancreas develops severe peripheral neuropathy with gemcitabine/nab paclitaxel as first-line therapy: 37m13s
  • Peripheral neuropathy associated with nab paclitaxel: 39m40s
  • Approach to first-line therapy for metastatic pancreatic cancer: 41m40s
  • Combination immunotherapeutic approaches under investigation for advanced pancreatic cancer: 45m25s
  • Efficacy and tolerability of the pegylated recombinant human hyaluronidase enzyme PEGPH20 in patients with advanced pancreatic cancer: 47m14s
  • Therapeutic options for patients with metastatic pancreatic cancer and disease progression on gemcitabine/nab paclitaxel: 51m25s
  • NAPOLI-1: Results of a Phase III trial of nanoliposomal irinotecan (nal-IRI) and 5-FU/leucovorin (LV) for metastatic pancreatic cancer after gemcitabine-based therapy: 57m15s
  • Palliative care for patients with metastatic pancreatic cancer: 1h0m15s
  • Case: A 54-year-old woman with locally advanced pancreatic cancer and refractory ascites: 1h4m45s
  • Case: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 1h8m44s
  • Case: A 62-year-old woman with pancreatic cancer and a solitary liver lesion receives FOLFIRINOX followed by stereotactic body radiation therapy: 1h12m55s

Select publications